NCT05747625View on ClinicalTrials.gov

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

March 1, 2030

Conditions
Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

Panitumumab

Given IV

DRUG

Zirconium Zr 89 Panitumumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Electronic Health Record Review

Ancillary studies

Trial Locations (1)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

Vanderbilt-Ingram Cancer Center

OTHER

lead

Eben Rosenthal

OTHER